Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 9, 2003, Pages 1543-1550

  Postma, Maarten J ^a   Kruidhof, Hanneke ^a   de Jong van den Berg, Lolkje T W ^a   de Zeeuw, Dick ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Angiotensin II receptor antagonists; Losartan; Pharmacoeconomics; RENAAL trial; Type 2 diabetes

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLUCOSE; INSULIN; IRBESARTAN; LOSARTAN POTASSIUM; PLACEBO; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HEALTH ECONOMICS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; METHODOLOGY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLICATION;

ANGIOTENSIN II; BIPHENYL COMPOUNDS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 0141566778     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.9.1543     Document Type: Article

References (48)

1. HOSTETTER. TH: Prevention of endstage renal disease due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:910-912.
2. RITZ E, ORTH SR: Nephropathy in Patients with Type 2 diabetes mellitus. N. Engl. J. Med. (1999) 341:1127-1133.
3. THE ACE INHIBITORS IN DIABETIC NEPHROPATHY TRIALIST GROUP: Should All Patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting-enzyme inhibitors? a meta-analysis of individual patient data. Ann. Intern. Med. (2001) 134:370-379.
4. MASCHIO G, ALBERTI D, JANIN G et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition In Progressive Renal Insufficiency (AIPRI) Group. N. Engl. J. Med. (1996) 334:939-945.
5. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibiton on diabetic nephropathy. N. Engl. J. Med. (1993) 329:1456-1462.
6. VAN HOUT BA, SIMEON GP, MCDONNELL J, MANN JFE: Economic evaluation of benazepril in chronic renal insufficiency. Kidney. Int. (1997) 52:S159-S162.
7. VAN BALLEGOOIE E, VAN EVERDINGEN JJE: Guidelines on diagnosis, treatment and prevention of complications in diabetes mellitus (in Dutch: CBO-richtlijnen over diagnostiek, behandeling en preventie van complicaties bij diabetes mellitus: retinopathie, voetulcera, nefropathie, en hart- en vaatziekten). Ned. Tijdschr. Geneeskd. (2000) 144:413-418.
8. GANSEVOORT RT, MEIJER RP, VULINK AJE et al.: A meta-analysis of the antihypertensive efficacy of angiotensin-II antagonists. Br. J. Clin. Pharmacol. (1999) 48:766P-783P.
9. COATS AJS: Angiotensin receptor blockers - finally the evidence is coming in: IDNT and RENAAL. Int. J. Cardiol. (2001) 79:99-102.
10. PARVING H-H, LEHNERT H, BRÖCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect if irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. For The Irbesartan In Patients With Type 2 Diabetes and Microalbuminuria Study Group. N. Engl. J. Med. (2001) 345:870-878.
11. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. For The Collaborative Study Group. N. Engl. J. Med. (2001) 345:851-860.
12. BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. For the RENAAL Study Investigators. N. Engl. J. Med. (2001) 345:861-869.
13. TAYLOR AA: Is there a place for combining angiotensin-converting-enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure? Curr. Opin. Nephrol. Hypertens. (2001) 10:643-648.
14. HOVIND P, ROSSING P, TARNOW L, SCHMIDT UM, PARVING HH: Progression of diabetic nephropathy. Kidney Int. (2001) 59:702-709.
15. TIMMERMANS PB, DUNCIA JV, CARINI et al.: Discovery of losartan, the first angiotensin II receptor antagonist. J. Hum. Hypertension. (1995) 9(Suppl. 5):S3-S18.
16. SICA DA, LO M-W, SHAW WC et al.: The pharmacokinetics of losartan in renal insufficiency. J. Hypertension (1995) (Suppl. 1):S49-S52.
17. BURNIER M, BRUNNER HR: Angiotensin-II-receptor antagonists. Lancet (2000) 35:637-645.
18. HUSTON P, PETERSON R: Withholding proven treatment in clinical research. N. Engl. J. Med. (2001) 345:912-914.
19. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
20. HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUCY INVESTIGATORS. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253-259.
21. LOPEZ A: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. (1994) 330:937.
22. EXNER DV, DRIES DL, DOMANSKI MJ, COHN JN: Lesser response to an angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. (2001) 344:135-137.
23. BRANCATI FL, WHITTLE JC, WHELTON PK, SEIDLER AJ, KLAG MJ: The Excess Incidence of Diabetic End-stage Renal Disease among Blacks: a population-based study of potential explanatory factors. JAMA (1992) 268:3079-3084.
24. WALSER M: Angiotensin-receptor blockers, Type 2 diabetes, and renoprotection. N. Engl. J. Med. (2002) 346:705.
25. AHUJA TS, FREEMAN D Jr, MAHNKEN JD et al.: Prediction of the development of hyperkalemia in patients using angiotensin-converting-enzyme inhibitors. Am. J. Nephrol. (2000) 20:268-272.
26. UKPDS GROUP: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes. Br. Med. J. (1998) 317:713-720.
27. ESTACIO RO, JEFFERS BW, GIFFORD N, SCHRIER RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care. (2000) 23(S2):B54-B64.
28. RUGGENENTI P, PERNA A, GHERARDI G, BENINI R, REMUZZI G: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney. Dis. (2000) 35:1155-1165.
29. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial agianst atenolol. For The Life Study Group. Lancet (2002) 359:995-1003.
30. BRIGGS A, O'BRIEN BJ, BACKHOUSE G: Thinking Outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Ann. Rev. Public. Health (2002) 23:377-401.
31. HERMAN WH, SHAHINFAR S, CARIDES GW et al.: Losartan reduces the costs associated with diabetic end-stage renal disease; The RENAAL study economic evaluation. Diabetes Care. (2003) 26:683-687.
32. PALMER AJ, ANNEMANS L, ROZE S et al.: The health-economic implications of the 'Irbesartan in Diabetic Nephropathy Trial' (IDNT) in France and Belgium. Value Health (2002) 5:546.
33. GOLAN L, BIRKMEYER JD, WELCH HG: The cost-effectiveness of treating all patients with Type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Intern. Med. (1999) 131:660-667.
34. RAVID M, SAVIN H, JUTRIN I et al.: Long-term stabilizing effect of angiotensin-converting-enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients. Ann. Intern. Med. (1993) 118:577-581.
35. RAVID M, BROSH D, LEVI Z, BAR-DAYAN Y, RAVID D, RACHMANI R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. (1998) 128:982-988.
36. HJELMGREN J, BERGGREN F, ANDERSSON F: Health economic guidelines - similarities, differences and some implications. Value Health (2001) 4:225-250.
37. ADLER AI, STEVENS RJ, MANLEY SE, BILOUS RW, CULL CA, HOLMAN RR: Development and progression of nephropathy in Type 2 diabetes: the United Kingdom Prospective Diabetes Study. UKPDS Group. Kidney Int. (2003) 63:225-232.
38. VAN OS N, NIESSEN LW, BILO HJG, CASPARIE AF, VAN HOUT BA: Diabetes nephropathy in the Netherlands: a cost-effectiveness analysis of national clinical guidelines. Health Policy (2000) 51:135-147.
39. EASTMAN RC, JAVITT JC, HERMAN WH, HASBACH EJ, DONG F: Model of complications of NIDDM; model construction and assumptions. Diabetes Care (1997) 20:725-734.
40. BRIGGS A, SCULPHER M: An introduction to markov modelling for economic evaluation. Pharmacoeconomics (1998) 4:397-409.
41. POSTMA MJ, KWIK J, RUTTEN WJMJ, DE JONG VAN DEN BERG LTW, BROUWERS JRBJ: Guidelines for Pharmaco-economic research in relation to published health-economic evaluations (in Dutch: Richtlijnen voor farmacoeconomisch onderzoek en gepubliceerde gezondheidseconomische studies). Ned. Tijdschr. Geneeskd. (2002) 146:1082-1087.
42. DELWEL GO, SPRENGER MJW: Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget (in Dutch: Farmaco-economsiche evaluatie van nieuwe geneesmiddelen). Ned. Tijdschr. Geneeskd. (2002) 146:1068-1071.
43. LACOURCIÈRE Y, BÉLANGER A, GODIN C et al.: Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy. Kidney Int. (2000) 58:762-779.
44. CASTELAO AM, RAMOS R, SANCHEZ-ZAMORANO MA, ALSINA J: Comparison of losartan versus enalapril in Type 2 diabetes mellitus patients with diabetic nephropathy. J. Am. Soc. Neprol. (1999) 10:127A
45. DE GRAUW WJC, VAN DE LISDONK EH, VAN DEN HOOGEN HJM et al.: Screening for microalbuminuria in Type 2 diabetic patients: the evaluation of a dipstick test in general practice. Diabetic Med. (1995) 12:657-663.
46. RUSSO D, PISANI A, BALLETTA et al.: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney Dis. (1999) 33:851-856.
47. ABRAHAMIAN H, PRAGER R: Senkung der kardiovaskulären morbidität und mortalität durch antihypertensive kombinationstherapie bei patienten mit Typ 2 diabetes mellitus. Wien Med Wochenschr. (2002) 9:210-214.
48. NAKAO N, YOSHIMURA A, MORITA H et al.: Combination treatment of angiotensin-II-receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (2002) 361:117-124.